In melanoma, BRAF and MEK inhibitors can induce an upregulation of the transcription factor PAX3, which in turn stimulates the expression of the microphthalmia-associated transcription factor (MITF), ultimately promoting cell survival [34]. Here, BRAF is linked to melanoma.